ISU Abxis Co. Ltd (086890) - Total Liabilities
Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has total liabilities worth ₩45.29 Billion KRW (≈ $30.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of ISU Abxis Co. Ltd to see how much of total assets are deployed in long-term investments.
ISU Abxis Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how ISU Abxis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ISU Abxis Co. Ltd total assets.
ISU Abxis Co. Ltd Competitors by Total Liabilities
The table below lists competitors of ISU Abxis Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Company K Partners Limited
KQ:307930
|
Korea | ₩8.74 Billion |
|
NEW ZEALAND RURAL
F:8UK
|
Germany | €216.89 Million |
|
Erbud SA
WAR:ERB
|
Poland | zł1.37 Billion |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
USA | $9.90 Million |
|
Kazia Therapeutics Ltd ADR
NASDAQ:KZIA
|
USA | $14.36 Million |
|
Gedeon Richter PLC
LSE:0QFP
|
UK | £249.71 Billion |
|
Rent the Runway Inc
NASDAQ:RENT
|
USA | $266.00 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down ISU Abxis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ISU Abxis Co. Ltd (086890) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ISU Abxis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual total liabilities of ISU Abxis Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩59.37 Billion ≈ $40.23 Million |
-54.17% |
| 2023-12-31 | ₩129.55 Billion ≈ $87.79 Million |
+77.81% |
| 2022-12-31 | ₩72.86 Billion ≈ $49.38 Million |
-7.94% |
| 2021-12-31 | ₩79.14 Billion ≈ $53.63 Million |
+102.03% |
| 2020-12-31 | ₩39.17 Billion ≈ $26.55 Million |
+4.24% |
| 2019-12-31 | ₩37.58 Billion ≈ $25.47 Million |
+271.87% |
| 2018-12-31 | ₩10.11 Billion ≈ $6.85 Million |
-35.69% |
| 2017-12-31 | ₩15.71 Billion ≈ $10.65 Million |
+10.23% |
| 2016-12-31 | ₩14.26 Billion ≈ $9.66 Million |
-39.11% |
| 2015-12-31 | ₩23.41 Billion ≈ $15.87 Million |
-25.87% |
| 2014-12-31 | ₩31.59 Billion ≈ $21.41 Million |
-- |
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more